Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes

NCT03061188 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT03061188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03061188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Lead sponsor
Northwestern University
Phase
Phase 1
Overall status
Completed
Start date
May 23, 2017
Completion date
August 4, 2020
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid neoplasm, aggressive non-hodgkin lymphoma, recurrent solid neoplasm, refractory mantle cell lymphoma, t-cell non-hodgkin lymphoma, unresectable solid neoplasm